NanoViricides, Inc. is a nano-biopharmaceutical company whose business goals are to discover, develop and commercialize therapeutics (nanoviricides™) to advance the care of patients suffering from life-threatening viral infections.
NanoViricides, Inc. is a development stage company. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal influenza, HIV, Epidemic Kerato-Conjunctivitis (EKC), hepatitis C, rabies, dengue fever, and Ebola virus, among others.
A nanoviricide is created by chemically attaching a virus-binding ligand, derived from the binding site of the virus on its cell surface receptor, to a nanomicelle flexible polymer. This binding site does not change significantly when a virus mutates
Tailor-made design and selection of (1) the virus-binding ligand; and (2) the backbone "nanomicelle", separately, allows us to rapidly optimize drug candidates (a) against a number of viruses; (b) for desired pharmacokinetic characteristics (e.g. sustained effect); and (c) for different routes of administration. This versatility is unmatched in the Industry.
1 Controls Drive,
Shelton, CT 06484